Novartis oncology deal bolsters Array's shares
This article was originally published in Scrip
Executive Summary
Array BioPharma's share price leapt by 35% on 20 April after it signed a development deal with Novartis for its small molecule anticancer MEK inhibitors, including ARRY-162 and its back-up ARRY-300.